Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
2010 Standout
Novel therapeutic strategies targeting HIV integrase
2012
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
2010 Standout
Filgotinib suppresses HIV-1–driven gene transcription by inhibiting HIV-1 splicing and T cell activation
2020
The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity
2011 StandoutNobel
Allosteric Inhibitor Development Targeting HIV‐1 Integrase
2011
The CD85j+ NK Cell Subset Potently Controls HIV-1 Replication in Autologous Dendritic Cells
2008 StandoutNobel
T cell exhaustion
2011 Standout
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1
2004
Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS
2015
Interferon α–Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1
2012 StandoutNobel
New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin
2008 Standout
Immune reconstitution syndrome associated with opportunistic mycoses
2007
Actinohivin: specific amino acid residues essential for anti-HIV activity
2010 StandoutNobel
Functions of natural killer cells
2008 Standout
Lymphangiogenesis in development and human disease
2005 StandoutNature
NK cells in HIV infection: Paradigm for protection or targets for ambush
2005
Microbicides: A new frontier in HIV prevention
2006
Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
2014 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Antitumour effects of antiretroviral therapy
2004
A neglected epidemic: fungal infections in HIV/AIDS
2014
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein
2009
Kaposi's Sarcoma-associated Herpesvirus Activation of Vascular Endothelial Growth Factor Receptor 3 Alters Endothelial Function and Enhances Infection
2005
Regulation of STAT signalling by proteolytic processing
2004
Natural killer cells and innate immunity to protozoan pathogens
2004
Primary HIV Infection: Clinical Presentation, Testing, and Treatment
2017
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
The Role of Selenium in Inflammation and Immunity: From Molecular Mechanisms to Therapeutic Opportunities
2011 Standout
Molecular Biology and Pathology of Lymphangiogenesis
2008 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The yin‐yang of the interaction between myelomonocytic cells and NK cells
2018
Hepatitis C Virus (HCV)-Specific CD8+Cells Produce Transforming Growth Factor β That Can Suppress HCV-Specific T-Cell Responses
2007
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
2017 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Strong serological responses and HIV RNA increase following AS 03‐adjuvanted pandemic immunization in HIV ‐infected patients
2011
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection
2006
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
Long oligonucleotide microarrays for African green monkey gene expression profile analysis
2007 StandoutNobel
Characterization of CD56–/CD16+natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals
2005
Upregulation of IL-21 Receptor on B Cells and IL-21 Secretion Distinguishes Novel 2009 H1N1 Vaccine Responders from Nonresponders among HIV-Infected Persons on Combination Antiretroviral Therapy
2011
Role for plasmacytoid dendritic cells in anti‐HIV innate immunity
2005
Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals
2007 StandoutNobel
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Works of Silvia Nozza being referenced
The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT
2008
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption
2010
Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5Δ) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals
2001
Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis
2003
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells
2017
Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals
2010
B-cell subset alterations and correlated factors in HIV-1 infection
2013
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
2004
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up
2016
Oral CCR5 inhibitors: will they make it through?
2006
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
2016
Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy
2002